Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2000

View Archived Issues

Screening method based on spectral data offered by NIH for licensing

NIH offers molecules that influence pathogen resistance for licensing

NIH offers M-CSF antagonist for licensing as antiviral therapy

NIH offers S-nitrosoglutathione for licensing as AIDS therapy

NIH licensing opportunity: hematopoietic enhancement using prolactin

Palatin Technologies awarded phase I SBIR grant for pain management therapies

Flamel Technologies seeks approval of Genvir herpes therapy in France

GenVec begins phase II trials of BioByPass in PVD

Teverelix shows promise in first-dose-in-humans study

Further notice of serious hypersensitivity reactions associated with Ziagen issued by EMEA

Innogenetics commences phase I trial of therapeutic hepatitis C vaccine

Progenics and Pharmacopeia establish new antiviral drug discovery collaboration

Merz and Lundbeck to develop and market memantine for various CNS indications

Salix receives milestone payment from Shire for balsalazide

Phytera and Novelos Therapeutics enter collaborative agreement for novel cancer immunotherapy

QLT and Ciba Vision seek expanded labeling for Visudyne

Lundbeck's siramesine enters phase II development

New compounds interacting with muscarinic M3 receptor useful for urinary disorders

Analgesic agents under development at Banyu

DHEA evaluated for depression, AD and adrenal insufficiency

Kyowa Hakko claims new series of NF-kappaB inhibitors

Antifungal agents under study at Takeda

New series under development at Pharmacia for treatment of cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...